141 related articles for article (PubMed ID: 20102737)
21. Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats.
Quinney SK; Galinsky RE; Jiyamapa-Serna VA; Chen Y; Hamman MA; Hall SD; Kimura RE
Drug Metab Dispos; 2008 Jun; 36(6):1097-101. PubMed ID: 18339815
[TBL] [Abstract][Full Text] [Related]
22. Nebulization of nanoparticulate amorphous or crystalline tacrolimus--single-dose pharmacokinetics study in mice.
Sinswat P; Overhoff KA; McConville JT; Johnston KP; Williams RO
Eur J Pharm Biopharm; 2008 Aug; 69(3):1057-66. PubMed ID: 18406587
[TBL] [Abstract][Full Text] [Related]
23. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles.
Chen W; Gu B; Wang H; Pan J; Lu W; Hou H
Int J Pharm; 2008 Oct; 362(1-2):133-40. PubMed ID: 18585448
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation.
Tang J; Wei H; Liu H; Ji H; Dong D; Zhu D; Wu L
Drug Deliv; 2010 May; 17(4):223-30. PubMed ID: 20210560
[TBL] [Abstract][Full Text] [Related]
25. Dry powder inhaler formulations of poorly water-soluble itraconazole: A balance between in-vitro dissolution and in-vivo distribution is necessary.
Huang Z; Lin L; McGoverin C; Liu H; Wang L; Zhou QT; Lu M; Wu C
Int J Pharm; 2018 Nov; 551(1-2):103-110. PubMed ID: 30217767
[TBL] [Abstract][Full Text] [Related]
26. Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition.
Miller DA; DiNunzio JC; Yang W; McGinity JW; Williams RO
Drug Dev Ind Pharm; 2008 Aug; 34(8):890-902. PubMed ID: 18608468
[TBL] [Abstract][Full Text] [Related]
27. Fusion processing of itraconazole solid dispersions by kinetisol dispersing: a comparative study to hot melt extrusion.
DiNunzio JC; Brough C; Miller DA; Williams RO; McGinity JW
J Pharm Sci; 2010 Mar; 99(3):1239-53. PubMed ID: 19681106
[TBL] [Abstract][Full Text] [Related]
28. Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption.
Miller DA; DiNunzio JC; Yang W; McGinity JW; Williams RO
Pharm Res; 2008 Jun; 25(6):1450-9. PubMed ID: 18288449
[TBL] [Abstract][Full Text] [Related]
29. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media.
Matteucci ME; Brettmann BK; Rogers TL; Elder EJ; Williams RO; Johnston KP
Mol Pharm; 2007; 4(5):782-93. PubMed ID: 17715989
[TBL] [Abstract][Full Text] [Related]
30. Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles.
Chen W; Zhan C; Gu B; Meng Q; Wang H; Lu W; Hou H
J Drug Target; 2011 Apr; 19(3):228-34. PubMed ID: 20540685
[TBL] [Abstract][Full Text] [Related]
31. Avoidance of food effect on oral absorption profile of itraconazole by self-micellizing solid dispersion approach.
Kojo Y; Kobayashi K; Matsunaga S; Suzuki H; Seto Y; Sato H; Onoue S
Drug Metab Pharmacokinet; 2017 Oct; 32(5):273-276. PubMed ID: 28923421
[TBL] [Abstract][Full Text] [Related]
32. Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs.
Yin X; Daintree LS; Ding S; Ledger DM; Wang B; Zhao W; Qi J; Wu W; Han J
Drug Des Devel Ther; 2015; 9():2801-10. PubMed ID: 26060397
[TBL] [Abstract][Full Text] [Related]
33. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model.
McConville JT; Overhoff KA; Sinswat P; Vaughn JM; Frei BL; Burgess DS; Talbert RL; Peters JI; Johnston KP; Williams RO
Pharm Res; 2006 May; 23(5):901-11. PubMed ID: 16715380
[TBL] [Abstract][Full Text] [Related]
34. New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Nanomedicine; 2012; 7():5475-89. PubMed ID: 23093903
[TBL] [Abstract][Full Text] [Related]
35. Improved oral absorption profile of itraconazole in hypochlorhydria by self-micellizing solid dispersion approach.
Kojo Y; Matsunaga S; Suzuki H; Sato H; Seto Y; Onoue S
Eur J Pharm Sci; 2017 Jan; 97():55-61. PubMed ID: 27810562
[TBL] [Abstract][Full Text] [Related]
36. A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion.
Engers D; Teng J; Jimenez-Novoa J; Gent P; Hossack S; Campbell C; Thomson J; Ivanisevic I; Templeton A; Byrn S; Newman A
J Pharm Sci; 2010 Sep; 99(9):3901-22. PubMed ID: 20602348
[TBL] [Abstract][Full Text] [Related]
37. The Increased Dissolution and Oral Absorption of Itraconazole by Nanocrystals with an Endogenous Small-Molecule Surfactant as a Stabilizer.
Chang S; Yang Q; Liu J; Yin L; Han J; Zong L; Pu X
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675589
[TBL] [Abstract][Full Text] [Related]
38. Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.
Maincent JP; Najvar LK; Kirkpatrick WR; Huang S; Patterson TF; Wiederhold NP; Peters JI; Williams RO
Drug Dev Ind Pharm; 2017 Feb; 43(2):264-274. PubMed ID: 27645428
[TBL] [Abstract][Full Text] [Related]
39. Nanocrystal-based per-oral itraconazole delivery: superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug absorption.
Sarnes A; Kovalainen M; Häkkinen MR; Laaksonen T; Laru J; Kiesvaara J; Ilkka J; Oksala O; Rönkkö S; Järvinen K; Hirvonen J; Peltonen L
J Control Release; 2014 Apr; 180():109-16. PubMed ID: 24566254
[TBL] [Abstract][Full Text] [Related]
40. In Vitro and In Vivo Performance of Different Sized Spray-Dried Crystalline Itraconazole.
Kumar S; Jog R; Shen J; Zolnik B; Sadrieh N; Burgess DJ
J Pharm Sci; 2015 Sep; 104(9):3018-28. PubMed ID: 25195539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
